Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSD
Dates
study started
completion around
Principal Investigator
by Kathryn Gold, MD (ucsd)

Description

Summary

This is an open-label, randomized, phase II trial to test the efficacy of Ibrutinib in combination with either Nivolumab or Cetuximab in the treatment of recurrent and/or metastatic head an neck squamous cell carcinoma

Official Title

A Multi-Institutional, Open-Label, Randomized, Phase II Trial Of Ibrutinib In Combination With EGFR Inhibition Or PD-1 Inhibition In Patients With Recurrent/Metastatic Head And Neck Squamous Cell Carcinoma

Details

Keywords

Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck, oropharyngeal, Carcinoma, Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Nivolumab, Cetuximab, Ibrutinib, Ibrutinib 560mg PO daily (Imbruvica), Ibrutinib + Cetuximab, Ibrutinib + Nivolumab

Eligibility

Location

  • UCSD Moores Cancer Center
    La Jolla California 92093 United States

Lead Scientist at University of California Health

  • Kathryn Gold, MD (ucsd)
    Clinical Professor, Medicine, Vc-health Sciences-schools. Authored (or co-authored) 62 research publications

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Diego
ID
NCT03646461
Phase
Phase 2 research study
Study Type
Interventional
Participants
About 5 people participating
Last Updated